Erik Klapproth

532 total citations
21 papers, 356 citations indexed

About

Erik Klapproth is a scholar working on Oncology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Erik Klapproth has authored 21 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Erik Klapproth's work include Cardiac Fibrosis and Remodeling (5 papers), Metal complexes synthesis and properties (3 papers) and Ferrocene Chemistry and Applications (2 papers). Erik Klapproth is often cited by papers focused on Cardiac Fibrosis and Remodeling (5 papers), Metal complexes synthesis and properties (3 papers) and Ferrocene Chemistry and Applications (2 papers). Erik Klapproth collaborates with scholars based in Germany, Austria and United Kingdom. Erik Klapproth's co-authors include Michael A. Jakupec, Bernhard K. Keppler, Nils Cordes, Achim Temme, Robert Trondl, Ali El‐Armouche, Anne Vehlow, Christian G. Hartinger, Wolfgang Kandioller and Tamás Kiss and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and European Heart Journal.

In The Last Decade

Erik Klapproth

19 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erik Klapproth Germany 11 175 119 112 41 38 21 356
Georges Laı̈n France 9 107 0.6× 244 2.1× 108 1.0× 15 0.4× 22 0.6× 11 426
Rémy Morgentin France 13 173 1.0× 292 2.5× 301 2.7× 21 0.5× 15 0.4× 23 624
Mireille Bayle France 8 109 0.6× 210 1.8× 119 1.1× 12 0.3× 48 1.3× 10 406
Mohit Chhabra Australia 12 58 0.3× 152 1.3× 162 1.4× 82 2.0× 10 0.3× 17 377
Andrea Uecker Germany 9 82 0.5× 207 1.7× 119 1.1× 26 0.6× 4 0.1× 12 457
Ridong Li China 15 98 0.6× 387 3.3× 273 2.4× 25 0.6× 28 0.7× 42 666
Mark Charles United Kingdom 8 43 0.2× 205 1.7× 247 2.2× 48 1.2× 27 0.7× 9 498
Ratna Kumari India 10 128 0.7× 200 1.7× 114 1.0× 35 0.9× 9 0.2× 16 449
Kristin Janz United States 12 48 0.3× 216 1.8× 288 2.6× 10 0.2× 36 0.9× 14 536
Colin G. Barry United States 8 226 1.3× 248 2.1× 131 1.2× 20 0.5× 21 0.6× 9 467

Countries citing papers authored by Erik Klapproth

Since Specialization
Citations

This map shows the geographic impact of Erik Klapproth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Klapproth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Klapproth more than expected).

Fields of papers citing papers by Erik Klapproth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Klapproth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Klapproth. The network helps show where Erik Klapproth may publish in the future.

Co-authorship network of co-authors of Erik Klapproth

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Klapproth. A scholar is included among the top collaborators of Erik Klapproth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Klapproth. Erik Klapproth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klapproth, Erik, Christoph Becker‐Pauly, Sebastian Zeißig, et al.. (2025). Type I interferon limits interleukin-6 signalling in SLE through shedding interleukin-6 receptors. Lara D. Veeken. 64(11). 5793–5802.
2.
Künzel, Stephan R., Erik Klapproth, Mario Schubert, et al.. (2024). Radiation-induced morphea of the breast – characterization and treatment of fibroblast dysfunction with repurposed mesalazine. Scientific Reports. 14(1). 26132–26132.
3.
Klapproth, Erik, et al.. (2024). Intertwined regulators: hypoxia pathway proteins, microRNAs, and phosphodiesterases in the control of steroidogenesis. Pflügers Archiv - European Journal of Physiology. 476(9). 1383–1398. 5 indexed citations
4.
Künzel, Stephan R., et al.. (2023). Investigation of mesalazine as an antifibrotic drug following myocardial infarction in male mice. Physiological Reports. 11(17). e15809–e15809. 2 indexed citations
5.
Brock, Thomas D., Marianne Großer, Erik Klapproth, et al.. (2021). The Influence of VE-Cadherin on Adhesion and Incorporation of Breast Cancer Cells into Vascular Endothelium. International Journal of Molecular Sciences. 22(11). 6049–6049. 9 indexed citations
6.
Klapproth, Erik, et al.. (2021). Function and regulation of phosphatase 1 in healthy and diseased heart. Cellular Signalling. 90. 110203–110203. 10 indexed citations
7.
Klapproth, Erik, et al.. (2021). Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice. Naunyn-Schmiedeberg s Archives of Pharmacology. 394(11). 2233–2244. 7 indexed citations
8.
Klapproth, Erik, et al.. (2021). Genetic Deletion of Polo-Like Kinase 2 Induces a Pro-Fibrotic Pulmonary Phenotype. Cells. 10(3). 617–617. 9 indexed citations
9.
Künzel, Stephan R., Erik Klapproth, Jan‐Heiner Küpper, et al.. (2020). Modeling atrial fibrosis in vitro —Generation and characterization of a novel human atrial fibroblast cell line. FEBS Open Bio. 10(7). 1210–1218. 13 indexed citations
10.
Emig, Ramona, Mario Schubert, Erik Klapproth, et al.. (2020). Repurposing mesalazine against cardiac fibrosis in vitro. Naunyn-Schmiedeberg s Archives of Pharmacology. 394(3). 533–543. 10 indexed citations
11.
Klapproth, Erik, et al.. (2020). ADAM10 inhibition improves survival and augments cardiac function after myocardial infarction. European Heart Journal. 41(Supplement_2). 1 indexed citations
12.
Klapproth, Erik, Christopher Piorkowski, Manuel Mayr, et al.. (2020). PLK2 is a novel regulator of osteopontin-driven fibrosis and diastolic dysfunction in permanent atrial fibrillation. European Heart Journal. 41(Supplement_2). 4 indexed citations
13.
Vehlow, Anne, Erik Klapproth, Sha Jin, et al.. (2019). Interaction of Discoidin Domain Receptor 1 with a 14-3-3-Beclin-1-Akt1 Complex Modulates Glioblastoma Therapy Sensitivity. Cell Reports. 26(13). 3672–3683.e7. 56 indexed citations
14.
Klapproth, Erik, Ellen Dickreuter, Falk Zakrzewski, et al.. (2018). Whole exome sequencing identifies mTOR and KEAP1 as potential targets for radiosensitization of HNSCC cells refractory to EGFR and β1 integrin inhibition. Oncotarget. 9(26). 18099–18114. 15 indexed citations
15.
Vehlow, Anne, Erik Klapproth, Katja Storch, et al.. (2017). Adhesion- and stress-related adaptation of glioma radiochemoresistance is circumvented by β1 integrin/JNK co-targeting. Oncotarget. 8(30). 49224–49237. 30 indexed citations
16.
Kubanik, Mario, Wolfgang Kandioller, Robert F. Anderson, et al.. (2016). Towards targeting anticancer drugs: ruthenium(ii)–arene complexes with biologically active naphthoquinone-derived ligand systems. Dalton Transactions. 45(33). 13091–13103. 44 indexed citations
17.
Klapproth, Erik, Christine Unger, Irene Lichtscheidl, et al.. (2015). Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Investigational New Drugs. 33(4). 835–847. 43 indexed citations
18.
Kurzwernhart, Andrea, Erik Klapproth, Michael A. Jakupec, et al.. (2015). Flavonoid‐Based Organometallics with Different Metal Centers – Investigations of the Effects on Reactivity and Cytotoxicity. European Journal of Inorganic Chemistry. 2016(2). 240–246. 23 indexed citations
19.
Kurzwernhart, Andrea, Erik Klapproth, Michael A. Jakupec, et al.. (2015). Flavonoid-Based Organometallics with Different Metal Centers - Investigations of the Effects on Reactivity and Cytotoxicity: Flavonoid-Based Organometallics with Different Metal Centers. 1 indexed citations
20.
Bacher, Felix, Éva A. Enyedy, Nóra V. Nagy, et al.. (2013). Copper(II) Complexes with Highly Water-Soluble l- and d-Proline–Thiosemicarbazone Conjugates as Potential Inhibitors of Topoisomerase IIα. Inorganic Chemistry. 52(15). 8895–8908. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Georges Laı̈n Breakdown of academic impact, for papers by Rémy Morgentin Breakdown of academic impact, for papers by Mireille Bayle Breakdown of academic impact, for papers by Mohit Chhabra Breakdown of academic impact, for papers by Andrea Uecker Breakdown of academic impact, for papers by Ridong Li Breakdown of academic impact, for papers by Mark Charles Breakdown of academic impact, for papers by Ratna Kumari Breakdown of academic impact, for papers by Kristin Janz Breakdown of academic impact, for papers by Colin G. Barry
Rankless by CCL
2026